Acadia Pharmaceuticals (ACAD) Enterprise Value (2010 - 2026)

Acadia Pharmaceuticals' Enterprise Value history runs 17 years deep, the most recent figure standing at -$851.5 million for Q1 2026.

• In Q1 2026, Enterprise Value fell 24.92% year-over-year to -$851.5 million; the TTM figure through Mar 2026 stood at -$851.5 million (down 24.92% YoY), while the FY2025 annual figure was -$819.7 million, down 8.43% from the prior year.
• Enterprise Value for Q1 2026 stood at -$851.5 million, down from -$819.7 million in the prior quarter.
• The five-year high for Enterprise Value was -$345.9 million in Q3 2023, with the low at -$851.5 million in Q1 2026.
• The 5-year median for Enterprise Value is -$470.5 million (2024), against an average of -$562.0 million.
• The sharpest annual moves came in 2022 and 2024: Enterprise Value increased 22.81% in 2022, then slumped 72.26% in 2024.
• Acadia Pharmaceuticals' Enterprise Value stood at -$416.8 million in 2022, then retreated by 5.29% to -$438.9 million in 2023, then slumped by 72.26% to -$756.0 million in 2024, then slipped by 8.43% to -$819.7 million in 2025, then decreased by 3.88% to -$851.5 million in 2026.
• Business Quant data shows ACAD's Enterprise Value at -$851.5 million in Q1 2026, -$819.7 million in Q4 2025, and -$847.0 million in Q3 2025.